These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 25363612)

  • 1. Active surveillance for localized prostate cancer: an analysis of patient contacts and utilization of healthcare resources.
    Thomsen FB; Berg KD; Røder MA; Iversen P; Brasso K
    Scand J Urol; 2015 Feb; 49(1):43-50. PubMed ID: 25363612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Active surveillance strategy for patients with localised prostate cancer: criteria for progression.
    Thomsen FB
    Dan Med J; 2015 Feb; 62(2):. PubMed ID: 25634510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Decade of Active Surveillance in the PRIAS Study: An Update and Evaluation of the Criteria Used to Recommend a Switch to Active Treatment.
    Bokhorst LP; Valdagni R; Rannikko A; Kakehi Y; Pickles T; Bangma CH; Roobol MJ;
    Eur Urol; 2016 Dec; 70(6):954-960. PubMed ID: 27329565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Long-Term Risks of Metastases in Men on Active Surveillance for Early Stage Prostate Cancer.
    Maggi M; Cowan JE; Fasulo V; Washington SL; Lonergan PE; Sciarra A; Nguyen HG; Carroll PR
    J Urol; 2020 Dec; 204(6):1222-1228. PubMed ID: 33157570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utilization of Active Surveillance and Watchful Waiting for localized prostate cancer in the daily practice.
    Herden J; Weissbach L
    World J Urol; 2018 Mar; 36(3):383-391. PubMed ID: 29330583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing the relationship between statin use and oncologic outcomes among men electing active surveillance for localized prostate cancer.
    Nyame YA; Wilkins L; Greene DJ; Ganesan V; Dai C; Almassi N; Stephenson AJ; Gong M; Berglund R; Klein EA
    Prostate Cancer Prostatic Dis; 2019 Dec; 22(4):617-623. PubMed ID: 30996285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comprehensive analysis of cost of an active surveillance cohort compared to radical prostatectomy as primary treatment for prostate cancer.
    Pozo C; Hernández V; Capitán C; de la Peña E; Fernández-Conejo G; Martínez MDM; Del Riego S; Pérez-Fernández E; Llorente C
    World J Urol; 2019 Jul; 37(7):1297-1303. PubMed ID: 30276542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Biopsy Compliance on Outcomes for Patients on Active Surveillance for Prostate Cancer.
    Detsky JS; Ghiam AF; Mamedov A; Commisso K; Commisso A; Zhang L; Liu S; Klotz L; Loblaw A; Vesprini D
    J Urol; 2020 Nov; 204(5):934-940. PubMed ID: 32330406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors Associated with Time to Conversion from Active Surveillance to Treatment for Prostate Cancer in a Multi-Institutional Cohort.
    Cooley LF; Emeka AA; Meyers TJ; Cooper PR; Lin DW; Finelli A; Eastham JA; Logothetis CJ; Marks LS; Vesprini D; Goldenberg SL; Higano CS; Pavlovich CP; Chan JM; Morgan TM; Klein EA; Barocas DA; Loeb S; Helfand BT; Scholtens DM; Witte JS; Catalona WJ;
    J Urol; 2021 Nov; 206(5):1147-1156. PubMed ID: 34503355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changing Trends in Surgical Management of Prostate Cancer: The End of Overtreatment?
    Huland H; Graefen M
    Eur Urol; 2015 Aug; 68(2):175-8. PubMed ID: 25736732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Follow-up in Active Surveillance for Prostate Cancer: Strict Protocol Adherence Remains Important for PRIAS-ineligible Patients.
    Soeterik TFW; van Melick HHE; Dijksman LM; Biesma DH; Witjes JA; van Basten JA
    Eur Urol Oncol; 2019 Sep; 2(5):483-489. PubMed ID: 31411970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of Differential Patterns of Oxidative Biomarkers in Prostate Cancer Progression.
    Wu T; Kasper S; Wong RM; Bracken B
    Clin Genitourin Cancer; 2020 Apr; 18(2):e174-e179. PubMed ID: 31899150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Active surveillance can reduce overtreatment in patients with low-risk prostate cancer.
    Thomsen FB; Røder MA; Hvarness H; Iversen P; Brasso K
    Dan Med J; 2013 Feb; 60(2):A4575. PubMed ID: 23461989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Clinical Significance of Multiple Negative Surveillance Prostate Biopsies for Men on Active Surveillance-Does Cancer Vanish or Simply Hide?
    Chu CE; Cowan JE; Fasulo V; Washington SL; de la Calle C; Shoemaker J; Carroll PR
    J Urol; 2021 Jan; 205(1):109-114. PubMed ID: 33198555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Secondary chemoprevention of localized prostate cancer by short-term androgen deprivation to select indolent tumors suitable for active surveillance: a prospective pilot phase II study.
    Cussenot O; Cornu JN; Drouin SJ; Mozer P; Egrot C; Vaessen C; Haab F; Bitker MO; Rouprêt M
    World J Urol; 2014 Apr; 32(2):545-50. PubMed ID: 24166289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Compliance Rates with the Prostate Cancer Research International Active Surveillance (PRIAS) Protocol and Disease Reclassification in Noncompliers.
    Bokhorst LP; Alberts AR; Rannikko A; Valdagni R; Pickles T; Kakehi Y; Bangma CH; Roobol MJ;
    Eur Urol; 2015 Nov; 68(5):814-21. PubMed ID: 26138043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transurethral resection of the prostate for patients with Gleason score 6 prostate cancer and symptomatic prostatic enlargement: a risk-adaptive strategy for the era of active surveillance.
    Koo KC; Park SU; Rha KH; Hong SJ; Yang SC; Hong CH; Chung BH
    Jpn J Clin Oncol; 2015 Aug; 45(8):785-90. PubMed ID: 25979243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Healthcare costs among men with favorable risk prostate cancer managed with observation strategies versus immediate treatment in an integrated healthcare system.
    Kariburyo F; Wang Y; Cheng IE; Wang L; Morgenstern D; Asner I; Xie L; Meadows E; Danella J
    J Med Econ; 2017 Aug; 20(8):825-831. PubMed ID: 28534659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Final pathohistology after radical prostatectomy in patients eligible for active surveillance (AS).
    Lellig E; Gratzke C; Kretschmer A; Stief C
    World J Urol; 2015 Jul; 33(7):917-22. PubMed ID: 26047652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Active Surveillance for Prostate Cancer in a Real-life Cohort: Comparing Outcomes for PRIAS-eligible and PRIAS-ineligible Patients.
    Soeterik TFW; van Melick HHE; Dijksman LM; Biesma DH; Witjes JA; van Basten JA
    Eur Urol Oncol; 2018 Aug; 1(3):231-237. PubMed ID: 31102626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.